Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1

Status

Completed 109Terminated 34Recruiting 7Withdrawn 6Unknown 6Active not recruiting 4Not yet recruiting 3Suspended 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 3Genitourinary 2Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 56Biliary Tract Neoplasms 24Cholangiocarcinoma 23Nasopharyngeal Carcinoma 22Carcinoma, Non-Small-Cell Lung 22Urinary Bladder Neoplasms 18Breast Neoplasms 18Neoplasm Metastasis 17Lung Neoplasms 14Lymphoma, Large B-Cell, Diffuse 13Colorectal Neoplasms 12Carcinoma, Transitional Cell 12Recurrence 9Non-Muscle Invasive Bladder Neoplasms 9Sarcoma 8Ovarian Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasms 7Gallbladder Neoplasms 7Hodgkin Disease 6Nasopharyngeal Neoplasms 5Bile Duct Neoplasms 5Adenocarcinoma 5Uterine Cervical Neoplasms 4Locally Advanced Pancreatic Cancer 4Endometrial Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Adenocarcinoma 3Osteosarcoma 3Lymphoma, T-Cell, Peripheral 3

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Gemcitabine × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT06623656 2026-04-21

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Weill Medical College of Cornell University

Phase 2 Recruiting
112 enrolled
Thoracic

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT05382559 2026-04-14

A Study of ASP3082 in Adults With Advanced Solid Tumors

Astellas Pharma Inc

Phase 1 Recruiting
681 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT06360354 2026-03-31

MTAPESTRY 103

Amgen

Phase 1 Recruiting
350 enrolled
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting
105 enrolled
Tumor-Agnostic

Neoplasms

NCT07019220 2025-06-13

COBRA

Medical University of Vienna

Phase 2 Recruiting
47 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT06696742 2024-11-20

PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡